logo
#

Latest news with #cognitiveSymptoms

Teens Oversleeping Post-Concussion May Have Worse Recovery
Teens Oversleeping Post-Concussion May Have Worse Recovery

Medscape

time02-07-2025

  • Health
  • Medscape

Teens Oversleeping Post-Concussion May Have Worse Recovery

TOPLINE: Kids and teens sleeping longer, even as little as an hour more, during the first week after a concussion were more likely to have worse cognitive and somatic symptoms. Sleeping longer was also linked to persistent symptoms and slower recovery. METHODOLOGY: Researchers used data from a randomized clinical trial that took place across three emergency pediatric departments in Ontario, Canada, over a 2-year period beginning in March 2017. The study included 291 kids and teens between the ages of 10 and 18 years (median age, 13.2 years; 44% female) who received treatment for a concussion within 48 hours of injury. Each patient wore an accelerometer on their waist 24 hours a day for 2 weeks and completed sleep logs to monitor sleep patterns. Symptoms were tracked using the Health and Behavior Inventory (HBI), a questionnaire that measures cognitive and somatic symptoms at 1 , 2 , and 4 weeks following their concussion. Symptom change was measured using conservative (z score ≥ 1.65) and liberal (z score ≥ 1.28) cutoffs; estimates were measured in HBI units. TAKEAWAY: Kids and teens who slept 10.5 vs 9.5 hours per night during the first week after a concussion had higher symptom scores at 1 week (estimate, 1.3; 95% CI, 0.25-2.28). Longer sleep duration was linked to higher odds of persisting symptoms at 4 weeks (conservative: odds ratio [OR], 1.73; 95% CI, 0.91-3.26; liberal: OR, 1.93; 95% CI, 1.07-3.47). Teens who slept 10.9 vs 9.9 hours were more likely to have increased symptoms at 4 weeks (estimate, 2.2; 95% CI, 0.85-3.47). IN PRACTICE: 'Long sleep duration may be associated with increased odds of being reliably symptomatic at 4 weeks, therefore a greater risk of PSAC [persisting symptoms after a concussion],' the study authors wrote. 'Clinicians should monitor youths' sleep after concussion.' SOURCE: This study was led by Lauren Butterfield, MSc, of the Children's Hospital of Eastern Ontario Research Institute in Ottawa, Canada. It was published online on June 18 in JAMA Network Open. LIMITATIONS: The HBI used for symptom assessment is not validated for youths older than 16.99 years, and 16 participants were older than 17 years. Recruitment from three Canadian pediatric emergency departments may have introduced sampling bias. DISCLOSURES: Various study authors reported receiving stipend support, research grants, and travel awards from the Children's Hospital of Eastern Ontario Research Institute, the Canadian Institutes of Health Research, and the Canadian Concussion Network, among others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Karolinska Development's portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study
Karolinska Development's portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study

Yahoo

time26-05-2025

  • Business
  • Yahoo

Karolinska Development's portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study

STOCKHOLM, SWEDEN – May 26, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has resumed the inclusion of patients to the clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. In March, Umecrine Cognition announced that the study had been halted due to technical issues in the production of capsules used in the study, which, however, had no impact on patient safety. Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company's most advanced drug candidate, golexanolone, is currently being evaluated in a randomized, double-blind, placebo-controlled phase 1b/2a clinical study in patients with primary biliary cholangitis (PBC) who experience clinically significant fatigue and cognitive symptoms. Karolinska Development's ownership in Umecrine Cognition amounts to 73%. For further information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: Johan Dighed, General Counsel and Deputy CEO, Karolinska Development ABPhone: +46 70 207 48 26, e-mail: TO THE EDITORS About Karolinska Development ABKarolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patient's lives while providing an attractive return on investment to shareholders. Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success. Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases. The company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network. For more information, please visit Attachment KD Umecrine Cognition resumes eng

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store